S100A11 and metabolic dysfunction-associated steatohepatitis: Zhou et al. (2017) found that in a mouse NAFLD model generated by a western diet (40% fat and 0.2% cholesterol) treatment, the expression of S100A11 was significantly upregulated in the liver. Another study using a mouse model of non-alcoholic steatohepatitis treated with a high fat/high cholesterol diet (20% fat and 1% cholesterol) showed that S100A11 increased in the liver in a time-dependent manner (Oh et al., 2013).